Ranbaxy CEO Looks Past U.S. FDA Troubles To Expanded Generics Sales
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories, which has had problems with U.S. regulators in the past few years, plans to expand its sales in the market, with a specific aim to be first on the market with newly approved generics.